COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,015 Articles (22,627 medRxiv, 8,388 bioRxiv)

Most recent first Previous |  Page 1231: Articles 12301-12310  | Next

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
Wirnsberger, G., Monteil, V., Eaton, B., Postnikova, E., Murphy, M., Braunsfeld, B., Crozier, I., Kricek, F., Niederhoefer, J., Schwarzboeck, A., Breid, H., Sanchez Jimenez, A., Bugajska-Schretter, A., Dohnal, A., Ruf, C., Gugenberger, R., Hagelkrueys, A., Montserrat, N., Holbrook, M., Oostenbrink, C., Shoemaker, R. H., Mirazimi, A., Penninger, J. M.
10.1101/2021.09.10.459744 — Posted: 2021-09-10 Discussion: Onsite
Pharmacological perturbation of intracellular dynamics as a SARS-CoV-2 antiviral strategy
Bakhache, W., Partiot, E., Lucansky, V., Bare, Y., Bonaventure, B., Goujon, C., Bories, C., Deffieu, M. S., Gaudin, R.
10.1101/2021.09.10.459410 — Posted: 2021-09-10
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns
Rothen, D. A., Krenger, P. S., Nonic, A., Balke, I., Vogt, A.-C., Chang, X., Manenti, A., Vedovi, F., Resevica, G., Walton, S., Zeltins, A., Montomoli, E., Vogel, M., Bachmann, M. F., Mohsen, M. O.
10.1101/2021.09.10.459749 — Posted: 2021-09-10
Differential antibody dynamics to SARS-CoV-2 infection and vaccination
Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zuiani, A., Habibi, S., Gautam, A., Xiao, T., Cai, Y., Chen, B., Wesemann, D. R.
10.1101/2021.09.09.459504 — Posted: 2021-09-10
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
Barsi, S., Papp, H., Valdeolivas Urbelz, A., Toth, D. J., Kuczmog, A., Madai, M., Hunyady, L., Varnai, P., Saez-Rodriguez, J., Jakab, F., Szalai, B.
10.1101/2021.09.10.459786 — Posted: 2021-09-10
pH-dependent polymorphism of the structure of SARS-CoV-2 nsp7
Lee, Y., Tonelli, M., Rahimi, M., Anderson, T. K., Kirchdoerfer, R. N., Henzler-Wildman, K., Lee, W.
10.1101/2021.09.10.459800 — Posted: 2021-09-10
COVID-19 Vaccine Concerns about Safety, Effectiveness and Policies in the United States, Canada, Sweden, and Italy among Unvaccinated Individuals
Piltch-Loeb, R., Harriman, N., Healey, J., Bonetti, M., Toffolutti, V., Testa, M., Su, M., Savoia, E.
10.1101/2021.09.09.21263328 — Posted: 2021-09-10
Epidemic Models for COVID-19 during the First Wave from February to May 2020: a Methodological Review
Garin, M., Limnios, M., Nicolai, A., Bargiotas, I., Boulant, O., Chick, S. E., Dib, A., Evgeniou, T., Fekom, M., Kalogeratos, A., Labourdette, C., Ovchinnikov, A., Porcher, R., Pouchol, C., Vayatis, N.
10.1101/2021.09.02.21263033 — Posted: 2021-09-10
Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021
Elliott, P., Haw, D. J., Wang, H., Eales, O., Walters, C. E., Ainslie, K. E. C., Atchison, C. J., Fronterre, C., Diggle, P., Page, A. J., Trotter, A., Prosolek, S. J., The COVID-19 Genomics UK (COG-UK) consortium, , Ashby, D., Donnelly, C., Barclay, W., Taylor, G. P., Cooke, G., Ward, H., Darzi, A., Riley, S.
10.1101/2021.09.02.21262979 — Posted: 2021-09-10 Discussion: Onsite
metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials
Evrenoglou, T., Boutron, I., Chaimani, A.
10.1101/2021.09.07.21263207 — Posted: 2021-09-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).